Invitae Corporation (NVTA)
(Delayed Data from NYSE)
$24.76 USD
+0.60 (2.48%)
Updated May 3, 2019 04:02 PM ET
After-Market: $24.77 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.76 USD
+0.60 (2.48%)
Updated May 3, 2019 04:02 PM ET
After-Market: $24.77 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Will Genetic Testing Drive Invitae's (NVTA) Q2 Earnings?
by Zacks Equity Research
Invitae (NVTA) expects to deliver a strong second quarter, banking on solid performance of its genetic testing business.
Invitae (NVTA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed at $25.76 in the latest trading session, marking a +0.39% move from the prior day.
Bear of the Day: Illumina (ILMN)
by Kevin Cook
The NASA of biotech just hit a growth speed-bump on its way to helping the world explore ancestry and disease
Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed at $24.47 in the latest trading session, marking a -0.04% move from the prior day.
Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed at $22.62 in the latest trading session, marking a -1.74% move from the prior day.
Invitae (NVTA) Catches Eye: Stock Jumps 9.1%
by Zacks Equity Research
Invitae (NVTA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Why These Innovative Biotech ETFs Are Soaring
by Neena Mishra
Strong M&A activity has sent shares of many small, innovative biotech companies surging
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
46 and You: Genetic Testing = Giant Growth Market
by Kevin Cook
Advances in genomic diagnostic technology have made testing affordable for the 99.0% of the world still in line.
Bull of the Day: Illumina (ILMN)
by Kevin Cook
The NASA of biotech is helping the world explore crucial genetic information to understand ancestry and disease
2 Healthcare Innovators To Buy Now
by Kevin Cook
My innovation radar is hot on the trail of genetic diagnostics and advanced medical records IT.
Invitae (NVTA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of -2.17% and -12.85%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Invitae (NVTA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerner (CERN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner (CERN) in Q1. However, expected decline in bookings is likely to be a dampener.
Invitae (NVTA) Scales a New 52-Week High on Solid Prospects
by Zacks Equity Research
One of the key growth drivers for Invitae (NVTA) is an increase in billable tests over the past year.
Invitae (NVTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Invitae (NVTA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.
Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of 4.26% and 8.59%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Invitae (NVTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Sweta Killa
Sector ETF report for ARKG
Implied Volatility Surging for Invitae (NVTA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Zacks Equity Research
Sector ETF report for ARKG
Invitae (NVTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of 16.07% and 21.54%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Cerner (CERN) Looks Good: Stock Adds 6.2% in Session
by Zacks Equity Research
Cerner (CERN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Zacks Equity Research
Sector ETF report for ARKG